{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T23:17:33Z","timestamp":1725405453047},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The indications for continuous oral anticoagulant treatment, the target interval and the procedures for withdrawing treatment have changed in the last 10 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients on continuous oral anticoagulant treatment at the Outpatient Anticoagulant Clinic at Ume\u00e5 University Hospital in 2002 were included in a descriptive study (n = 900). 263 of those had a mechanical heart valve prosthesis. Only patient records for patients with other indications than mechanical heart valve prosthesis were examined. 582 of those records were found. In the 55 remaining patients some clinical information was retrieved from the computerised warfarin dosage database. These latter, more unsure clinical data, are presented separately. Anticoagulant treatment was discontinued if lack of proper indication or presence of too high risk for hemorrhagic complications were found.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The prevalence of continuous oral anticoagulant treatment in the uptake area was 0.65%. The most common target interval was INR 2.1\u20133.0, but patients with a mechanical heart valve prosthesis were often treated more aggressively, i.e. with a higher INR target interval. Of the patients on continuous treatment, 26.6% of the INR values were outside 2.0\u20133.0. The most common reasons for oral anticoagulant treatment were atrial fibrillation or mechanical heart valve prosthesis, in contrast to earlier findings in studies of our population in 1987 and 1990. We found 90 patients (10.0%) without proper indication for oral anticoagulant treatment or too high risk, and their treatment was discontinued.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In patients on oral anticoagulant therapy, re-evaluation of indications and risks resulted in a substantial number of treatment withdrawals. There have been major changes in treatment indications during the last decade, possibly due to rapid development of knowledge in the field of thrombosis risk factors. Treatment should be re-considered once a year.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-9560-3-20","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T19:13:48Z","timestamp":1134069228000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study"],"prefix":"10.1186","volume":"3","author":[{"given":"Kim","family":"Ekblom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Hultdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Carlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tage","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,8]]},"reference":[{"issue":"32-33","key":"39_CR1","first-page":"3388","volume":"96","author":"H Johnsson","year":"1999","unstructured":"Johnsson H: [Anticoagulant therapy can be safer. An active follow-up and written care programs reduce the number of complications]. Lakartidningen 1999, 96(32-33):3388-3390.","journal-title":"Lakartidningen"},{"issue":"18","key":"39_CR2","first-page":"1871","volume":"165","author":"T Holm","year":"2003","unstructured":"Holm T, Lassen JF: [How many patients are on oral anticoagulant therapy in Denmark? Methods to estimate the number]. Ugeskr Laeger 2003, 165(18):1871-1875.","journal-title":"Ugeskr Laeger"},{"key":"39_CR3","unstructured":"Stigendal L, Johnsson H: Apekumarol ers\u00e4tts nu med waran, exempel p\u00e5 patientinformation. In Information fr\u00e5n L\u00e4kemedelsverket. Volume 9. Medical Products Agency; 1998."},{"issue":"32-33","key":"39_CR4","first-page":"3421","volume":"96","author":"A Taghavi","year":"1999","unstructured":"Taghavi A, Jonson T, Stockelberg D: [Survey of complications following treatment with anticoagulants. A computerized search for hemorrhagic complications completes manual reporting]. Lakartidningen 1999, 96(32-33):3421-3424.","journal-title":"Lakartidningen"},{"issue":"4","key":"39_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/02813439508996774","volume":"13","author":"JH Jansson","year":"1995","unstructured":"Jansson JH, Westman G, Boman K, Nilsson T, Norberg B: Oral anticoagulant treatment in a medical care district--a descriptive study. Scand J Prim Health Care 1995, 13(4):268-274.","journal-title":"Scand J Prim Health Care"},{"key":"39_CR6","doi-asserted-by":"crossref","unstructured":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators N Engl J Med 1990, 323(22):1505-1511.","DOI":"10.1056\/NEJM199011293232201"},{"key":"39_CR7","doi-asserted-by":"crossref","unstructured":"Stroke Prevention in Atrial Fibrillation Study. Final results Circulation 1991, 84(2):527-539.","DOI":"10.1161\/01.CIR.84.2.527"},{"key":"39_CR8","doi-asserted-by":"crossref","unstructured":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group Lancet 1993, 342(8882):1255-1262.","DOI":"10.1016\/0140-6736(93)92358-Z"},{"issue":"2","key":"39_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","volume":"18","author":"SJ Connolly","year":"1991","unstructured":"Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991, 18(2):349-355.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"39_CR10","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","volume":"327","author":"MD Ezekowitz","year":"1992","unstructured":"Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327(20):1406-1412.","journal-title":"N Engl J Med"},{"issue":"8631","key":"39_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","volume":"1","author":"P Petersen","year":"1989","unstructured":"Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989, 1(8631):175-179. 10.1016\/S0140-6736(89)91200-2","journal-title":"Lancet"},{"issue":"7","key":"39_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/archinte.160.7.967","volume":"160","author":"GP Samsa","year":"2000","unstructured":"Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J: Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000, 160(7):967-973. 10.1001\/archinte.160.7.967","journal-title":"Arch Intern Med"},{"issue":"1 Suppl","key":"39_CR13","doi-asserted-by":"publisher","first-page":"194S","DOI":"10.1378\/chest.119.1_suppl.194S","volume":"119","author":"GW Albers","year":"2001","unstructured":"Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 2001, 119(1 Suppl):194S-206S. 10.1378\/chest.119.1_suppl.194S","journal-title":"Chest"},{"issue":"3","key":"39_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11936-002-0003-7","volume":"4","author":"SR Deitcher","year":"2002","unstructured":"Deitcher SR, Carman TL: Deep Venous Thrombosis and Pulmonary Embolism. Curr Treat Options Cardiovasc Med 2002, 4(3):223-238.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"7","key":"39_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa035422","volume":"349","author":"C Kearon","year":"2003","unstructured":"Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349(7):631-639. 10.1056\/NEJMoa035422","journal-title":"N Engl J Med"},{"issue":"7","key":"39_CR16","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1538-7836.2004.00813.x","volume":"2","author":"PM Ridker","year":"2004","unstructured":"Ridker PM: Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes. J Thromb Haemost 2004, 2(7):1034-1037. 10.1111\/j.1538-7836.2004.00813.x","journal-title":"J Thromb Haemost"},{"issue":"15","key":"39_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348(15):1425-1434. 10.1056\/NEJMoa035029","journal-title":"N Engl J Med"},{"issue":"6","key":"39_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/00005650-197111000-00007","volume":"9","author":"HM Tufo","year":"1971","unstructured":"Tufo HM, Speidel JJ: Problems with medical records. Med Care 1971, 9(6):509-517.","journal-title":"Med Care"},{"issue":"11","key":"39_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.7326\/0003-4819-124-11-199606010-00004","volume":"124","author":"SD Fihn","year":"1996","unstructured":"Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH: The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996, 124(11):970-979.","journal-title":"Ann Intern Med"},{"issue":"3","key":"39_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1046\/j.1365-2141.2003.04110.x","volume":"120","author":"P Froom","year":"2003","unstructured":"Froom P, Miron E, Barak M: Oral anticoagulants in the elderly. Br J Haematol 2003, 120(3):526-528. 10.1046\/j.1365-2141.2003.04110.x","journal-title":"Br J Haematol"},{"issue":"2","key":"39_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","volume":"105","author":"RJ Beyth","year":"1998","unstructured":"Beyth RJ, Quinn LM, Landefeld CS: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105(2):91-99. 10.1016\/S0002-9343(98)00198-3","journal-title":"Am J Med"},{"issue":"23","key":"39_CR22","first-page":"2472, 2474","volume":"61","author":"CA Thompson","year":"2004","unstructured":"Thompson CA: Ximelagatran data fail to impress FDA. Am J Health Syst Pharm 2004, 61(23):2472, 2474-5, 2480.","journal-title":"Am J Health Syst Pharm"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-9560-3-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:12:51Z","timestamp":1630480371000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/1477-9560-3-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1186\/1477-9560-3-20","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"10 July 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"20"}}